{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:01:31Z","timestamp":1784815291114,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007515","name":"University of Valladolid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007515","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.medcli.2026.107497","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T17:51:28Z","timestamp":1782669088000},"page":"107497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monoterapia con glucocorticoides frente a combinaci\u00f3n con metotrexato o tocilizumab en arteritis de c\u00e9lulas gigantes: eficacia y seguridad a 78 semanas en un estudio de cohortes retrospectivo"],"prefix":"10.1016","volume":"166","author":[{"given":"Javier","family":"Gamazo-Herrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Vela-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rodr\u00edguez-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"G\u00f3mez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mart\u00edn-Asenjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Cusacovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gonz\u00e1lez-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2026.107497_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.medcli.2026.107497_bib0130","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/jbmr.3523","article-title":"Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions","volume":"33","author":"Balasubramanian","year":"2018","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.medcli.2026.107497_bib0135","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.42920","article-title":"Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials","volume":"76","author":"Figueroa-Parra","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2026.107497_bib0140","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2026.107497_bib0145","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2026.107497_bib0150","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.rdc.2023.03.005","article-title":"Giant Cell Arteritis and Polymyalgia Rheumatica","volume":"49","author":"Nepal","year":"2023","journal-title":"Rheum Dis Clin North Am."},{"key":"10.1016\/j.medcli.2026.107497_bib0155","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2026.107497_bib0160","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s11739-024-03722-4","article-title":"Faster steroid-free remission with tocilizumab compared to methotrexate in giant cell arteritis: a real-life experience in two reference centres","volume":"19","author":"Quartuccio","year":"2024","journal-title":"Intern Emerg Med."},{"key":"10.1016\/j.medcli.2026.107497_bib0165","first-page":"723","article-title":"Giant cell arteritis in clinical practice: beyond GiACTA","volume":"44","author":"Regola","year":"2025","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.medcli.2026.107497_bib0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2026.107497_bib0175","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2026.107497_bib0180","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.medcli.2026.107497_bib0185","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","article-title":"European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency","volume":"109","author":"Beuschlein","year":"2024","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.medcli.2026.107497_bib0190","doi-asserted-by":"crossref","first-page":"103580","DOI":"10.1016\/j.autrev.2024.103580","article-title":"Relapses in giant cell arteritis: Updated review for clinical practice","volume":"23","author":"Alba","year":"2024","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.medcli.2026.107497_bib0195","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/art.39596","article-title":"Incidence of Severe Infections and Infection-Related Mortality During the Course of Giant Cell Arteritis: A Multicenter, Prospective, Double-Cohort Study","volume":"68","author":"Schmidt","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.medcli.2026.107497_bib0200","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/jcm11041034","article-title":"Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis","volume":"11","author":"Castan","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.medcli.2026.107497_bib0205","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/keab507","article-title":"All-cause and cause-specific mortality in patients with giant cell arteritis: a nationwide, population-based cohort study","volume":"61","author":"Therkildsen","year":"2022","journal-title":"Rheumatology."},{"key":"10.1016\/j.medcli.2026.107497_bib0210","doi-asserted-by":"crossref","first-page":"e864","DOI":"10.1016\/S2665-9913(22)00260-0","article-title":"Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis","volume":"4","author":"Scolnik","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.medcli.2026.107497_bib0215","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol."},{"key":"10.1016\/j.medcli.2026.107497_bib0220","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.medcli.2026.107497_bib0225","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.medcli.2026.107497_bib0230","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3899\/jrheum.181306","article-title":"Methotrexate in Giant Cell Arteritis Deserves a Second Chance \u2014 A High-dose Methotrexate Trial Is Needed","volume":"46","author":"Brouwer","year":"2019","journal-title":"J Rheumatol."},{"key":"10.1016\/j.medcli.2026.107497_bib0235","doi-asserted-by":"crossref","first-page":"keaf499","DOI":"10.1093\/rheumatology\/keaf499","article-title":"Methylprednisolone plus MTX-based regime vs. prednisone-based standard of care for GCA: a propensity score study","volume":"65","author":"Soto-Peleteiro","year":"2026","journal-title":"Rheumatology."},{"key":"10.1016\/j.medcli.2026.107497_bib0240","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.semarthrit.2021.01.006","article-title":"Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients","volume":"51","author":"Calder\u00f3n-Goercke","year":"2021","journal-title":"Semin Arthritis Rheum."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326001478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775326001478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:14:16Z","timestamp":1784812456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775326001478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0025775326001478"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107497","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoterapia con glucocorticoides frente a combinaci\u00f3n con metotrexato o tocilizumab en arteritis de c\u00e9lulas gigantes: eficacia y seguridad a 78 semanas en un estudio de cohortes retrospectivo","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2026.107497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"107497"}}